시장보고서
상품코드
1429310

세계 아달리무맙, 인플릭시맙 및 에타넙셉트 바이오시밀러 시장 보고서(2024년)

Adalimumab, Infliximab and Etanercept Biosimilars Global Market Report 2024

발행일: | 리서치사: The Business Research Company | 페이지 정보: 영문 250 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    


■ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

아달리무맙, 인플릭시맙 및 에타넙셉트 바이오시밀러 시장 규모는 앞으로 수년간 빠르게 성장할 것으로 예상됩니다. 2028년 복합 연간 성장률(CAGR) 11.4%를 나타낼 전망이며 67억 9,000만 달러로 성장할 것으로 예상됩니다. 예측 기간 동안 예상되는 성장은 건강 관리 비용 증가, 인구 고령화 및 건강 관리 접근성 향상으로 인한 것일 수 있으며, 이들 모두는 시장 성장을 가속하는 태세를 갖고 있습니다. 예측 기간 동안 예상되는 중요한 동향은 신제품 출시에 집중적인 노력, 합병 및 인수에 대한 전략적 중점, 전략적 파트너십 확립에 적극적인 접근, 투자 증가에 대한 중점 강화가 포함됩니다.

아달리무맙, 인플릭시맙 및 에타넙셉트 바이오시밀러 시장 진입은 브랜드 의약품의 특허 만료에 의해 촉진됩니다. 주목할만하게, 브랜드 의약품물 레미케이드의 특허 만료 후 FDA는 포스피라의 인플렉트라를 승인하고, 미국에서 관절염 류마티스, 성인 궤양성 대장염, 심상성 건선 등 다양한 자가면역 질환의 치료가 가능하게 되었습니다 했습니다. 마찬가지로 EU에서 암젠 엠브렐의 특허가 만료됨에 따라 엠브렐의 바이오시밀러인 베네파리가 유럽 위원회에 의해 승인되었습니다. 휴미라의 특허 해지 후, FDA에 의한 휴미라의 여섯 번째 바이오시밀러인 Hulio의 최근 승인(2020년 7월)을 포함하여 여러 바이오시밀러를 시장에서 사용할 수 있게 되었습니다. 그 결과, 휴미라, 엠블렐, 레미케이드 등의 브랜드 생물제제의 특허 만료에 의해 아달리무맙, 인플릭시맙 및 에타넙셉트 바이오시밀러 시장 수요가 촉진될 것으로 예상됩니다.

자가면역 질환의 유병률 확대로 아달리무맙, 인플릭시맙 및 에타넙셉트 바이오시밀러 시장의 성장이 촉진될 것으로 예상됩니다. 자가면역 질환은 면역계의 기능 장애로 인해 발생하며 면역 세포가 신체의 건강한 세포를 공격합니다. 아달리무맙, 인플릭시맙 및 에타넙셉트는 종양 괴사 인자(TNF)α 억제제를 포함하는 생물학적 제제로서 다양한 자가면역 질환의 치료에 사용됩니다. 존스 홉킨스 대학에 따르면 2023년 미국에서는 인구의 3%에 해당하는 약 1,000만명이 다양한 자가면역 질환에 걸려 있다고 합니다. 그 결과, 자가면역질환의 유병률의 급증은 아달리무맙, 인플릭시맙 및 에타넙셉트 바이오시밀러 시장의 성장 촉진에 크게 기여하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 거시경제 시나리오

  • 고인플레이션이 시장에 미치는 영향
  • 우크라이나,러시아 전쟁이 시장에 미치는 영향
  • COVID-19에 의한 시장에 대한 영향

제5장 세계 시장 규모와 성장

  • 세계 시장 성장 촉진요인과 억제요인
    • 시장 성장 촉진요인
    • 시장 성장 억제요인
  • 세계 시장 규모 실적과 성장(2018년-2023년)
  • 세계 시장 규모 예측과 성장(2023년-2028년, 2033년)

제6장 시장 세분화

  • 세계 아달리무맙, 인플릭시맙 및 에타넙셉트 바이오시밀러 시장 : 제품별 세분화, 분석 및 예측(2018년-2023년, 2023년-2028년, 2033년)
  • 아달리무마브 바이오시밀러(Exemptia, Mabura, Hyrimoz, Hadlima, Abrilada, 기타)
  • 인플릭시맙 바이오시밀러(Inflectra, Renflexis, Ixifi, Avsola)
  • 시플맙(Erelzi, Eticovo)
  • 세계 아달리무맙, 인플릭시맙 및 에타넙셉트 바이오시밀러 시장, 유통 채널별 세분화, 분석 및 예측(2018년-2023년, 2023년-2028년, 2033년)
  • 병원 약국
  • 소매 약국
  • 온라인 약국
  • 세계 아달리무맙, 인플릭시맙 및 에타넙셉트 바이오시밀러 시장 : 용도별 세분화, 분석 및 예측(2018년-2023년, 2023년-2028년, 2033년)
  • 크론병
  • 건선성 관절염
  • 류마티스 관절
  • 궤양성 대장염
  • 강직성 척추염
  • 심상성 건선
  • 기타 용도

제7장 지역 및 국가 분석

  • 세계 아달리무맙, 인플릭시맙 및 에타넙셉트 바이오시밀러 시장 : 지역별, 분석 및 예측(2018년-2023년, 2023년-2028년, 2033년)
  • 세계 아달리무맙, 인플릭시맙 및 에타넙셉트 바이오시밀러 시장 : 국가별, 분석 및 예측(2018년-2023년, 2023년-2028년, 2033년)

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

  • 아달리무맙, 인플릭시맙 및 에타넙셉트 바이오시밀러 시장 경쟁 구도
  • 아달리무맙, 인플릭시맙 및 에타넙셉트 바이오시밀러 시장 기업 프로파일
    • Biogen
    • Novartis(Sandoz)
    • Pfizer
    • Amgen
    • Celltrion

제31장 기타 선도적이고 혁신적인 기업

  • 삼성바이오에피스(삼성생물)
  • Hetero Drugs Limited
  • Fresenius Kabi AG
  • Boehringer Ingelheim
  • Biocon
  • Zydus Lifesciences Limited
  • Reliance Life Sciences
  • Torrent Pharmaceuticals Ltd
  • Sun Pharmaceutical Industries Ltd
  • Cipla Limited
  • Zhejiang Hisun Pharmaceutical Co. Ltd
  • Bio-Thera Solutions, Ltd
  • Innovent Biologics(Suzhou) Co. Ltd
  • Janssen Biologics BV
  • Shanghai CP Guojian Pharmaceutical Co. Ltd

제32장 경쟁 벤치마킹

제33장 경쟁 대시보드

제34장 주요 인수합병(M&A)

제35장 미래 전망과 가능성 분석

제36장 부록

BJH 24.03.21

Adalimumab, infliximab, and etanercept biosimilars represent an innovative class of medications designed to inhibit the effects of the inflammatory mediator tumor necrosis factor-alpha (TNF-alpha). Infliximab biosimilars, in particular, are chimeric monoclonal antibodies targeting TNF-alpha and are utilized in the treatment of immune system disorders.

These medications include various products such as adalimumab, infliximab, cipleumab, and etanercept. Adalimumab, classified as a biological drug, operates on the immune system to mitigate inflammation. Its diverse applications encompass treating conditions such as Crohn's disease, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, ankylosing spondylitis, plaque psoriasis, and others. These products are made available through different distribution channels, including hospital pharmacies, retail pharmacies, and online pharmacies.

The adalimumab, infliximab, and etanercept biosimilars market research report is one of a series of new reports from The Business Research Company that provides adalimumab, infliximab, and etanercept biosimilars market statistics, including adalimumab, infliximab, and etanercept biosimilars industry global market size, regional shares, competitors with adalimumab, infliximab, and etanercept biosimilars market. This adalimumab, infliximab, and etanercept biosimilars market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The adalimumab, infliximab and etanercept biosimilars market size has grown exponentially in recent years. It will grow from $3.67 billion in 2023 to $4.41 billion in 2024 at a compound annual growth rate (CAGR) of 20.3%. The growth observed in the historical period can be attributed to several factors, including an upsurge in healthcare expenditure, regulatory changes, government initiatives, and the escalation of healthcare costs.

The adalimumab, infliximab and etanercept biosimilars market size is expected to see rapid growth in the next few years. It will grow to $6.79 billion in 2028 at a compound annual growth rate (CAGR) of 11.4%. The anticipated growth in the forecast period can be attributed to an increase in healthcare expenditure, the aging population, and an enhanced accessibility to healthcare, all of which are poised to drive market growth. Significant trends expected in the forecast period involve a concentrated effort on launching new products, a strategic emphasis on mergers and acquisitions, a proactive approach to establishing strategic partnerships, and a heightened focus on increasing investments.

The entrance of biosimilars into the market for adalimumab, infliximab, and etanercept is facilitated by the patent expiration of branded drugs. Notably, the FDA approved Hospira's Inflectra post the patent expiry of the branded drug Remicade, enabling treatment for various autoimmune diseases such as rheumatoid arthritis, adult ulcerative colitis, and plaque psoriasis in the United States. Similarly, in the EU, Amgen's Enbrel patent expiration led to the approval of Benepali, a biosimilar of Enbrel, by the European Commission. Following the expiry of Humira's patent, multiple biosimilars have become available in the market, including the recent approval (July 2020) of Hulio, the sixth biosimilar of Humira by the FDA. Consequently, the patent expiry of branded biologic drugs such as Humira, Enbrel, and Remicade is expected to propel demand in the adalimumab, infliximab, and etanercept biosimilars market.

The escalating prevalence of autoimmune diseases is anticipated to drive growth in the market for adalimumab, infliximab, and etanercept biosimilars. Autoimmune diseases arise from immune system dysfunction, leading immune cells to attack the body's healthy cells. Adalimumab, infliximab, and etanercept, as biological drugs with tumor necrosis factor (TNF) alpha inhibitors, are employed in treating various autoimmune diseases. According to Johns Hopkins University in 2023, approximately 10 million individuals in the US, constituting 3% of the population, are affected by diverse autoimmune illnesses. Consequently, the surge in autoimmune diseases' prevalence significantly contributes to driving the growth of the adalimumab, infliximab, and etanercept biosimilars market.

The escalating costs associated with brand-name versions of biosimilar drugs have paved the way for the adoption of lower-cost biosimilar alternatives upon the expiry of their patents. Notably, the expenses linked to branded biological drugs have nearly doubled in recent years, exemplified by the cost surge of Humira, a top-selling drug, which exceeded $72,000 in 2020. The transition to cost-effective biosimilar drugs is primarily driven by the absence of clinically significant differences in safety and efficacy between biosimilars and the original biologics. A striking example is the Danish healthcare system's extensive shift to adalimumab biosimilars following the expiration of the patent for the original adalimumab product, Humira. This transition resulted in an impressive 82% reduction in medication costs.

Major companies in the adalimumab, infliximab, and etanercept biosimilars market are prioritizing the development of innovative products, such as citrate-free adalimumab, to offer enhanced services to consumers. Citrate-free adalimumab represents a formulation of the biological medication adalimumab devoid of citrate. For instance, in December 2022, Fresenius Kabi, a German-based manufacturer specializing in medicines and technologies for infusion, transfusion, and clinical nutrition, announced FDA approval for the biosimilar Idacio (adalimumab). This biosimilar is sanctioned for use in managing chronic autoimmune disorders across all permissible uses of the reference product. It has been meticulously crafted employing advanced analytical methodologies, intended for the treatment of various chronic conditions.

In February 2022, the Indian biopharmaceutical company Biocon Limited successfully acquired the biosimilar assets of Viatris, Inc., a U.S.-based biopharmaceutical and healthcare company, for a total of $3.34 billion. This strategic acquisition positions Biocon as a unique and vertically integrated global leader in biosimilars, providing an impetus for the expedited commercialization of its existing and future biosimilar portfolio on a global scale. The move is set to significantly enhance Biocon's product reach across international markets. Viatris, Inc. is recognized for its expertise in the development and specialization of biological and therapeutic agents.

Major companies operating in the adalimumab, infliximab and etanercept biosimilars market report are Biogen, Novartis (Sandoz), Pfizer, Amgen, Celltrion, Samsung Bioepis (Samsung Biologics), Hetero Drugs Limited, Fresenius Kabi AG, Boehringer Ingelheim, Biocon, Zydus Lifesciences Limited, Reliance Life Sciences, Torrent Pharmaceuticals Ltd., Sun Pharmaceutical Industries Ltd., Cipla Limited, Zhejiang Hisun Pharmaceutical Co. Ltd., Bio-Thera Solutions, Ltd., Innovent Biologics (Suzhou) Co. Ltd., Janssen Biologics BV, Shanghai CP Guojian Pharmaceutical Co. Ltd., Sansheng Guojian, Shanghai Junshi Biosciences Co. Ltd., Mabwell Bioscience Co. Ltd., LG Chem, Nippon Kayaku, Mochida Pharmaceutical Co. Ltd., mAbxience, Allergan, Microgen, Geropharm, Valenta, NovaMedica Veropharm, Biocad, Roche, Bristol-Myers Squibb, Celon Pharma, SynBio, Celgene Corporation, AstraZeneca, Merck & Co, Gilead Sciences, Regeneron Pharmaceuticals, Rani Therapeutics, Eli Lilly and Company, Emisphere Technologies Inc., Enteris BioPharma, Allena Pharmaceuticals, Abbvie, Johnson & Johnson, Ache, Eurofarma, Sanofi, Teva Pharmaceuticals, Oramed Pharmaceuticals, Entera Bio, Julphar, Hikma Pharmaceuticals, Mylan, BIOPHARMA-MEA, NeoTX, AID Genomics Limited, Altis Biologics, Cipla Medpro South Africa, Next Biosciences, Viome, Inqaba Biotechnical Industries (Pty) Ltd

North America was the largest region in the adalimumab, infliximab and etanercept biosimilars market in 2023. The regions covered in the adalimumab, infliximab and etanercept biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the adalimumab, infliximab and etanercept biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain

The adalimumab, infliximab, and etanercept biosimilars market consists of sales of Amgevita, Hyrimoz, and Idacio. Values in this market are "factory gate values," that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Adalimumab, Infliximab and Etanercept Biosimilars Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on adalimumab, infliximab and etanercept biosimilars market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for adalimumab, infliximab and etanercept biosimilars? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The adalimumab, infliximab and etanercept biosimilars market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

  • 1) By Product: Adalimumab Biosimilars; Infliximab Biosimilars; Cipleumab
  • 2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
  • 3) By Application: Crohn's Disease; Psoriatic Arthritis; Rheumatoid Arthritis; Ulcerative Colitis; Ankylosing Spondylitis; Plaque Psoriasis; Other Applications
  • Companies Mentioned: Biogen; Novartis (Sandoz); Pfizer; Amgen; Celltrion
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Adalimumab, Infliximab and Etanercept Biosimilars Market Characteristics

3. Adalimumab, Infliximab and Etanercept Biosimilars Market Trends And Strategies

4. Adalimumab, Infliximab and Etanercept Biosimilars Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Adalimumab, Infliximab and Etanercept Biosimilars Market Size and Growth

  • 5.1. Global Adalimumab, Infliximab and Etanercept Biosimilars Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Adalimumab, Infliximab and Etanercept Biosimilars Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Adalimumab, Infliximab and Etanercept Biosimilars Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Adalimumab, Infliximab and Etanercept Biosimilars Market Segmentation

  • 6.1. Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Adalimumab Biosimilars (Exemptia, Mabura, Hyrimoz, Hadlima, Abrilada, Others)
  • Infliximab Biosimilars (Inflectra, Renflexis, Ixifi, Avsola)
  • Cipleumab (Erelzi, Eticovo)
  • 6.2. Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • 6.3. Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Crohn's Disease
  • Psoriatic Arthritis
  • Rheumatoid Arthritis
  • Ulcerative Colitis
  • Ankylosing Spondylitis
  • Plaque Psoriasis
  • Other Applications

7. Adalimumab, Infliximab and Etanercept Biosimilars Market Regional And Country Analysis

  • 7.1. Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Adalimumab, Infliximab and Etanercept Biosimilars Market

  • 8.1. Asia-Pacific Adalimumab, Infliximab and Etanercept Biosimilars Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Adalimumab, Infliximab and Etanercept Biosimilars Market

  • 9.1. China Adalimumab, Infliximab and Etanercept Biosimilars Market Overview
  • 9.2. China Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Adalimumab, Infliximab and Etanercept Biosimilars Market

  • 10.1. India Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Adalimumab, Infliximab and Etanercept Biosimilars Market

  • 11.1. Japan Adalimumab, Infliximab and Etanercept Biosimilars Market Overview
  • 11.2. Japan Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Adalimumab, Infliximab and Etanercept Biosimilars Market

  • 12.1. Australia Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Adalimumab, Infliximab and Etanercept Biosimilars Market

  • 13.1. Indonesia Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Adalimumab, Infliximab and Etanercept Biosimilars Market

  • 14.1. South Korea Adalimumab, Infliximab and Etanercept Biosimilars Market Overview
  • 14.2. South Korea Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Adalimumab, Infliximab and Etanercept Biosimilars Market

  • 15.1. Western Europe Adalimumab, Infliximab and Etanercept Biosimilars Market Overview
  • 15.2. Western Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Adalimumab, Infliximab and Etanercept Biosimilars Market

  • 16.1. UK Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Adalimumab, Infliximab and Etanercept Biosimilars Market

  • 17.1. Germany Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Adalimumab, Infliximab and Etanercept Biosimilars Market

  • 18.1. France Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Adalimumab, Infliximab and Etanercept Biosimilars Market

  • 19.1. Italy Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Adalimumab, Infliximab and Etanercept Biosimilars Market

  • 20.1. Spain Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Adalimumab, Infliximab and Etanercept Biosimilars Market

  • 21.1. Eastern Europe Adalimumab, Infliximab and Etanercept Biosimilars Market Overview
  • 21.2. Eastern Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Adalimumab, Infliximab and Etanercept Biosimilars Market

  • 22.1. Russia Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Adalimumab, Infliximab and Etanercept Biosimilars Market

  • 23.1. North America Adalimumab, Infliximab and Etanercept Biosimilars Market Overview
  • 23.2. North America Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Adalimumab, Infliximab and Etanercept Biosimilars Market

  • 24.1. USA Adalimumab, Infliximab and Etanercept Biosimilars Market Overview
  • 24.2. USA Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Adalimumab, Infliximab and Etanercept Biosimilars Market

  • 25.1. Canada Adalimumab, Infliximab and Etanercept Biosimilars Market Overview
  • 25.2. Canada Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Adalimumab, Infliximab and Etanercept Biosimilars Market

  • 26.1. South America Adalimumab, Infliximab and Etanercept Biosimilars Market Overview
  • 26.2. South America Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Adalimumab, Infliximab and Etanercept Biosimilars Market

  • 27.1. Brazil Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Adalimumab, Infliximab and Etanercept Biosimilars Market

  • 28.1. Middle East Adalimumab, Infliximab and Etanercept Biosimilars Market Overview
  • 28.2. Middle East Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Adalimumab, Infliximab and Etanercept Biosimilars Market

  • 29.1. Africa Adalimumab, Infliximab and Etanercept Biosimilars Market Overview
  • 29.2. Africa Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Adalimumab, Infliximab and Etanercept Biosimilars Market Competitive Landscape And Company Profiles

  • 30.1. Adalimumab, Infliximab and Etanercept Biosimilars Market Competitive Landscape
  • 30.2. Adalimumab, Infliximab and Etanercept Biosimilars Market Company Profiles
    • 30.2.1. Biogen
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Novartis (Sandoz)
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Pfizer
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Amgen
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Celltrion
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Adalimumab, Infliximab and Etanercept Biosimilars Market Other Major And Innovative Companies

  • 31.1. Samsung Bioepis (Samsung Biologics)
  • 31.2. Hetero Drugs Limited
  • 31.3. Fresenius Kabi AG
  • 31.4. Boehringer Ingelheim
  • 31.5. Biocon
  • 31.6. Zydus Lifesciences Limited
  • 31.7. Reliance Life Sciences
  • 31.8. Torrent Pharmaceuticals Ltd
  • 31.9. Sun Pharmaceutical Industries Ltd
  • 31.10. Cipla Limited
  • 31.11. Zhejiang Hisun Pharmaceutical Co. Ltd
  • 31.12. Bio-Thera Solutions, Ltd
  • 31.13. Innovent Biologics (Suzhou) Co. Ltd
  • 31.14. Janssen Biologics BV
  • 31.15. Shanghai CP Guojian Pharmaceutical Co. Ltd

32. Global Adalimumab, Infliximab and Etanercept Biosimilars Market Competitive Benchmarking

33. Global Adalimumab, Infliximab and Etanercept Biosimilars Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Adalimumab, Infliximab and Etanercept Biosimilars Market

35. Adalimumab, Infliximab and Etanercept Biosimilars Market Future Outlook and Potential Analysis

  • 35.1 Adalimumab, Infliximab and Etanercept Biosimilars Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Adalimumab, Infliximab and Etanercept Biosimilars Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Adalimumab, Infliximab and Etanercept Biosimilars Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제